{"entity":{"id":"nct05308264","kind":"trial","name":"Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)","aka":[],"tldr":"A phase 1/2 trial of R906289 Monosodium (R289 Na) in myelodysplastic syndromes / neoplasms, run by Rigel Pharmaceuticals, now recruiting.","summary":"Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) is a phase 1/2 interventional study registered as NCT05308264 by Rigel Pharmaceuticals, with 86 participants planned, started 2022-09-12 and due to reach its primary completion in 2026-08. Interventions recorded: R906289 Monosodium (R289 Na).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05308264","url":"https://clinicaltrials.gov/study/NCT05308264"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mds"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["rigel-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05308264","phase":"1/2","setting":"An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies","sponsor":"Rigel Pharmaceuticals","enrolled":86,"outcomes":[]},"route":"/trials/nct05308264/","neighbours":{"cancer":[{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"company":[{"id":"rigel-pharmaceuticals","kind":"company","name":"Rigel Pharmaceuticals","route":"/companies/rigel-pharmaceuticals/"}]}}